FDA clears Motivista digital therapeutic for negative symptoms of schizophrenia
The FDA has granted 510(k) clearance to Motivista, a prescription digital therapeutic developed by Click Therapeutics for adults with negative symptoms of schizophrenia. The treatment is cleared as an adjunct to clinician-managed outpatient care, addressing symptoms that current medications targeting hallucinations and delusions do not effectively treat.
